yingweiwo

Minnelide sodium

Cat No.:V11542 Purity: ≥98%
Minnelide is a triptolide analogue that displays anti-tumor effects in many tumor types, especially pancreatic cancer.
Minnelide sodium
Minnelide sodium Chemical Structure CAS No.: 1254702-87-8
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
Other Sizes

Other Forms of Minnelide sodium:

  • Minnelide free acid
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Minnelide is a triptolide analogue that displays anti-tumor effects in many tumor types, especially pancreatic cancer. Minnelide can cause apoptosis.
Biological Activity I Assay Protocols (From Reference)
ln Vitro
Following treatment in the presence (but not in the absence) of phosphatase, pancreatic cancer cell lines treated with methylide (0-200 nM; 48 hours) demonstrated a significant reduction in cell viability [2].
ln Vivo
Minnelide (intraperitoneal injection; 0.1-0.6 mg/kg; once daily or twice daily) results in significant decreases in tumor weight and volume at the conclusion of treatment and increases survival in an orthotopic model of MIA PaCa-2-derived human pancreatic cancer incidence of pancreatic tumors [2]. Minnelide (ip; 0.42 mg/kg; once daily; 28 days) limits local spread of metastatic S2-013 cells and resulting in a decrease in mean tumor weight in a pancreatic cancer xenograft model [2]. Minnelide (intraperitoneal injection; 0.42 mg/kg, 0.21 mg/kg; once daily) produced tumor regression, and in human pancreatic cancer xenografts from SCID mice, tumors from Minnelide-treated animals displayed fibrosis and consolidation. The existence of shrinking core [2].
Cell Assay
Cell Viability Assay[2]
Cell Types: Pancreatic Cancer
Cell Types: S2-013, MIA PaCa-2, S2-VP10 and Panc-1 Cell
Tested Concentrations: 0.100 nM, 200 nM
Incubation Duration: 48 hrs (hours)
Experimental Results: Pancreatic Cancer Cell Lines diminished cell viability in vitro.
Animal Protocol
Animal/Disease Models: Pancreatic cancer orthotopic model of MIA PaCa 2-derived human pancreatic tumors in athymic nude mice [2]
Doses: 0.1-0.6 mg/kg
Route of Administration: intraperitoneal (ip) injection; intraperitoneal (ip) injection. 0.1-0.6 mg/kg; one time/day or twice (two times) daily
Experimental Results: Prevents the growth of pancreatic tumors in the body.

Animal/Disease Models: athymic nude mouse metastatic S2-013 cell line pancreatic cancer xenograft model [2]
Doses: 0.42 mg/kg
Route of Administration: intraperitoneal (ip) injection; intraperitoneal (ip) injection. 0.42 mg/kg; one time/day
Experimental Results: Prevented widespread spread from the primary injection site.

Animal/Disease Models: SCID mouse human pancreatic cancer xenograft [2]
Doses: 0.21 mg/kg, 0.42 mg/kg
Route of Administration: intraperitoneal (ip) injection; 0.42 mg/kg; one time/day
Experimental Results: diminished human xenografts from patients tumor burden.
References

[1]. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327-341.

[2]. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139.

Additional Infomation
Triptolide Analog is a water soluble analog of the diterpenoid triepoxide triptolide isolated from the Chinese herb Tripterygium wilfordii Hook.f., with potential antineoplastic activity. Upon intravenous administration, the triptolide analog inhibits heat shock protein 70 (HSP70) and prevents HSP70-mediated inhibition of apoptosis. This leads to both the induction of apoptosis and a reduction of cancer cell growth. HSP70, a molecular chaperone upregulated in various cancer cells, plays a key role in the inhibition of caspase-dependent and -independent apoptosis.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C21H25NA2O10P
Molecular Weight
514.3705
Exact Mass
514.098
CAS #
1254702-87-8
Related CAS #
1254885-39-6 (free acid);1254702-87-8 (sodium);
PubChem CID
46203139
Appearance
White to off-white solid powder
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
10
Rotatable Bond Count
4
Heavy Atom Count
34
Complexity
1010
Defined Atom Stereocenter Count
9
SMILES
P(=O)([O-])([O-])OC([H])([H])O[C@]1([H])[C@]2(C([H])(C([H])([H])[H])C([H])([H])[H])[C@]([H])([C@@]3([H])[C@]4([C@@]5(C([H])([H])[H])C([H])([H])C([H])([H])C6C(=O)OC([H])([H])C=6[C@]5([H])C([H])([H])[C@@]5([H])[C@]41O5)O3)O2.[Na+].[Na+]
InChi Key
ZHBJMVNZRZUQEP-KIKMAQITSA-L
InChi Code
InChI=1S/C21H27O10P.2Na/c1-9(2)19-14(30-19)15-21(31-15)18(3)5-4-10-11(7-26-16(10)22)12(18)6-13-20(21,29-13)17(19)27-8-28-32(23,24)25;;/h9,12-15,17H,4-8H2,1-3H3,(H2,23,24,25);;/q;2*+1/p-2/t12-,13-,14-,15-,17+,18-,19-,20+,21+;;/m0../s1
Chemical Name
disodium;[(1S,2S,4S,5S,7S,8R,9R,11S,13S)-1-methyl-17-oxo-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl]oxymethyl phosphate
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
H2O : ~93.33 mg/mL (~181.45 mM)
DMSO : ~16.67 mg/mL (~32.41 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 1.67 mg/mL (3.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 1.67 mg/mL (3.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.9441 mL 9.7206 mL 19.4413 mL
5 mM 0.3888 mL 1.9441 mL 3.8883 mL
10 mM 0.1944 mL 0.9721 mL 1.9441 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • Minnelide hydrolyses and decreases cell viability in pancreatic cancer cell lines. (A) In vitro enzymatic hydrolysis of Minnelide was performed with alkaline phosphatase in glycine buffer. The half-life of Minnelide under these conditions was 2 min. Left, degradation of Minnelide; right, generation of the parent compound, triptolide. (B) Pancreatic cancer cells (MIA PaCa-2, Panc-1, S2-013, and S2-VP10) were seeded in 96-well plates 24 hours before being exposed to either the inactive (without alkaline phosphatase) or the active (with alkaline phosphatase) form of Minnelide at the concentrations indicated. Cell viability was measured 48 hours after treatment and compared with untreated cells (control). Triptolide (200 nM) was used as a positive control. Statistical significance of results was calculated with the Student’s t test. Columns, mean; bars, SE (n = 4; *P < 0.05).[2]. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139.
  • Minnelide decreases pancreatic tumor growth in vivo and increases survival. MIA PaCa-2 cells (1 × 106) were injected into the tail of the pancreas of athymic Ncr nu/nu mice. (A) Kaplan-Meier analysis of animals injected with either triptolide (0.2 mg/kg), Minnelide (0.1 to 0.6 mg/kg QD or 0.15 mg/kg BID), or saline daily for 60 days; experiment was terminated on day 90. Treatment was started on day 12 after surgery. (B and C) Analysis of tumor volume (B) or tumor weight (C) from animals in (A). Numbers above columns represent number of animals that developed tumors over the number of animals studied. Columns, mean; bars, SE. (D) Table represents animals alive at start of treatment and end of experiment in each group indicated.[2]. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139.
  • Minnelide increases percent overall survival in an orthotopic xenograft mouse model. AsPC-1 cells (2 × 105) were injected into the tail of the pancreas of athymic Ncr nu/nu mice on day 1. Asterisk, censored because deaths were unrelated to pancreatic cancer. (A) On day 7 after surgery, mice were randomized and each group of 10 mice was intraperitoneally injected with Minnelide (0.42 mg/kg) or saline daily for 100 consecutive days. Saline-treated mice were euthanized when moribund. On day 100, the Minnelide-treated cohort (n = 10) was divided into two groups. One group (n = 5) continued to receive Minnelide (0.42 mg/kg), whereas treatment was terminated in the second group (n = 5; D/C; Stop Minnelide). Kaplan-Meier curve of the saline- or Minnelide-treated mice. Saline-treated mice had a mean survival of 36 days. All the animals in the Minnelide-treated group were alive at day 385 when the experiment was terminated. Survival lines are superimposed. (B and C) Graphs showing the average tumor volume (B) or tumor weight (C) of saline- or Minnelide-treated mice. (D) AsPC-1 cells (2 × 105) were injected into the tail of the pancreas of athymic Ncr nu/nu mice on day 1, and treatment with Minnelide (0.42 mg/kg) or saline was started after the death of the first animal on day 28. Animals in the saline group were sacrificed when moribund, and the experiment was terminated on day 75. Kaplan-Meier curve of the saline- or Minnelide-treated mice shows an increase in survival of Minnelide-treated animals. The median survival of saline-injected animals was 36 days.[2]. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139.
Contact Us